Hydroxyzine can prolong the QT interval, increasing the risk of potentially fatal arrhythmias like Torsades de Pointes [1]. This effect is dose-dependent and can be exacerbated by other factors [1].
What is Torsades de Pointes?
Torsades de Pointes is a specific type of ventricular tachycardia, a rapid heart rhythm originating in the ventricles. It is characterized by a unique ECG pattern where the QRS complexes appear to twist around the baseline [2]. This condition can lead to syncope (fainting) and sudden cardiac death [2].
Who is most at risk for hydroxyzine's cardiac effects?
Individuals with pre-existing conditions that prolong the QT interval, such as congenital long QT syndrome, electrolyte imbalances (low potassium, magnesium, or calcium), bradycardia (slow heart rate), or those taking other QT-prolonging medications, are at higher risk [1]. Elderly patients are also more susceptible [1].
What other medications can prolong the QT interval?
A wide range of medications can prolong the QT interval, including certain antiarrhythmics, antibiotics, antipsychotics, antidepressants, and antihistamines [3]. Co-administration of hydroxyzine with these drugs significantly increases the risk of QT prolongation and associated arrhythmias [1].
How is QT prolongation managed?
Management involves discontinuing hydroxyzine and any other offending agents. Prompt treatment of electrolyte imbalances and bradycardia is crucial. For Torsades de Pointes, immediate defibrillation may be necessary, along with intravenous magnesium sulfate [2].
What are the alternatives to hydroxyzine for anxiety and itching?
For anxiety, alternatives include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines, though the latter carry risks of dependence [4]. For pruritus (itching), topical corticosteroids, oral antihistamines with a lower QT-prolonging risk profile (like cetirizine or loratadine), or other classes of antipruritic medications may be considered [5].
When did regulatory bodies start warning about hydroxyzine and QT prolongation?
Concerns regarding hydroxyzine's potential for QT prolongation have been present for some time, leading to updated prescribing information and warnings from regulatory agencies like the U.S. Food and Drug Administration (FDA) [1].
Where can I find more information on drug safety and patent information?
Detailed information on drug safety profiles, including risks like QT prolongation, and patent exclusivity data can be found at DrugPatentWatch.com [6].